Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 13 hours ago
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
about 13 hours ago
The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a...
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
about 13 hours ago
MoonLake Immunotherapeutics announced positive phase 3 data of patients with psoriatic arthritis...
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
about 13 hours ago
Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the...
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
about 14 hours ago
Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract...
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
about 14 hours ago
Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a...
Labcorp nabs FDA green light for BRAF melanoma diagnostic
about 15 hours ago
The FDA has signed off on Labcorp’s companion diagnostic for patients with...
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
about 15 hours ago
AbCellera has reported phase 2 results “beyond even the most aggressive upside...
Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub
about 15 hours ago
Novo Nordisk and Amazon Web Services will partner to leverage AI and...
FDA issues alert in wake of BD recall of faulty needle sets that caused four deaths
about 16 hours ago
The FDA’s Center for Devices and Radiological Health issued an early alert...
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
about 16 hours ago
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French...
Silence brings the noise to Takeda with phase 2 blood cancer win
about 17 hours ago
A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary...
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
about 18 hours ago
Arpeggio Biosciences’ eight-year song has come to an end as the transcriptome...